Emerging Therapies in the Management of Sickle Cell Disease
Advertisement
Advertisement
Trending on HCPLive
1
New Dyslipidemia Guidelines Reveal Significant Gap in LDL-C and LLT Treatment Goals
2
Agios Ends Tebapivat Development in Sickle Cell Disease After Phase 2
3
How Does the FDA Approval of Risankizumab Impact Pediatric Psoriasis and PsA? With Amy Paller, MD
4
Counseling Patients On Exa-cel Gene Therapy Journey, With Haydar Frangoul, MD, MS
5